Raleigh, N.C. — [August 10, 2026] — Veranex, the industry’s first Innovation CRO (iCRO) redefining end-to-end MedTech development, today announced the appointment of Beth Moeller as Chief Commercial Officer.
Beth brings more than 20 years of leadership experience across the life sciences industry, with a proven track record of building commercial organizations, strengthening strategic partnerships, and driving growth across pharmaceutical, biotechnology, medical device, and diagnostics markets. Her appointment supports Veranex’s continued focus on expanding its commercial capabilities and creating a more connected client experience across the full innovation lifecycle.
Strengthening Veranex’s Global Commercial Strategy
Prior to joining Veranex, Moeller served as Vice President of Business Development, Commercialization and Outcome Research at ICON plc, where she led a global business development organization supporting a broad portfolio of commercialization, real-world evidence, medical device, health economics and outcomes, pricing, market access, and patient-centered services.
During her tenure, she helped significantly expand the business, develop a strong global opportunity pipeline, establish preferred partnerships with leading pharmaceutical organizations, and introduce integrated commercial models that strengthened client engagement across multiple service areas. She also founded the company’s first Commercial Operations function and helped build integrated systems and teams spanning sales analytics, business intelligence, proposals, contracts, pricing, forecasting, and financial reporting.
Her previous leadership experience also includes senior roles in clinical operations, finance, outsourcing, and acquisition integration at Aptiv Solutions and MannKind Corporation.
“Beth’s ability to connect client needs, commercial strategy, and operational execution makes her an exceptional addition to our leadership team,” said Megan Osorio, Chief Executive Officer of Veranex. “Her experience building integrated commercial organizations and supporting clients across complex development journeys will be instrumental as we continue to strengthen our market position and deliver greater value to innovators worldwide.”
Creating a More Connected Client Experience
As Chief Commercial Officer, Moeller will lead Veranex’s global commercial strategy, including business development, strategic partnerships, commercial operations, client engagement, and marketing. She will focus on strengthening how Veranex brings its integrated capabilities to market and helping clients more easily access the expertise they need across design and engineering, preclinical, clinical, regulatory, quality, and commercialization.
“Veranex has a unique opportunity to connect deep expertise across the development lifecycle and create greater value for clients at every stage of innovation,” said Moeller. “I’m excited to join the team, strengthen how we partner with clients, and build a commercial strategy that brings the full breadth of Veranex’s capabilities forward. Together, we can help innovators navigate complexity, make more informed decisions, and advance solutions that ultimately improve patients’ lives.”
Veranex is a global, fully integrated Innovation CRO dedicated to accelerating MedTech innovation from early concept through commercialization. Headquartered in Raleigh, N.C., and powered by more than 800 specialists worldwide, Veranex combines design & engineering, preclinical, clinical, regulatory, manufacturing, and market access expertise to deliver clarity, confidence, and speed—turning vision into velocity for device and diagnostics innovators.
For more information, visit Veranex.com